The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

The future of the global HIV response risks being undermined by shrinking funding and wavering political will, health leaders have warned as the International AIDS Society (IAS) Conference on HIV ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The World Health Organization now recommends lenacapavir, a twice-yearly injectable HIV prevention drug, especially for high-risk groups. This endorse ...

As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...

Conference on HIV Science officially opened Monday in the Rwandan capital of Kigali, with a strong call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global ...

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according to a press release .

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

A breakthrough HIV drug that only needs to be injected twice a year to offer near-total protection from the virus and developing AIDS should be made available "immediately" at pharmacies, clinics and ...

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice ...

New data from Africa and Latin America shows rising infections, stalled treatment, and strained health systems Kampala, Uganda | RONALD MUSOKE | Scientists, researchers, policy makers and HIV/AIDS ...

Global progress against AIDS is at risk as US funding cuts threaten life-saving programs. Experts warn of millions of ...